Our findings support the use of brusatol, an Nrf2 inhibitor, combined with VCR as a novel therapeutic approach for the treatment of drug-insensitive or relapsed B-ALL. This evidence concerns the gene NFE2L2 and acute lymphoblastic leukemia.